



Bal Pharma Limited

09.09.2024

The Manager-Listing Compliance
National Stock Exchange of India Ltd
Mumbai.

BSE Limited
Mumbai.

Dear Sir,

Sub: Outcome of the Board Meeting.
Ref: Regulation 30 of SEBI(LODR) Regulations, 2015.

With reference to the above, Board of Directors of the Company has met today and *inter alia* transacted the following business.

1. Decided to commence the setting up of a green field project at Kadechur KIADB industrial area, Yadgir District at the cost of Rs.30 crores in the first phase. The Active Pharmaceutical ingredients (API) manufacturing facility proposed to be set up at the above mentioned location is designed to meet the stringent regulatory requirements of the developed markets. The project is expected to be completed in 36 months and the said facility will have initial production capacity of 120 tonne's of API's and intermediates per annum and will cater to the domestic and international markets.

This additional API production facility at Kadechur in Karnataka is expected to enhance the API manufacturing capacity of the Company, in addition to the existing API manufacturing facilities located at Bangalore, Udaipur in Rajasthan and Sangli in Maharashtra.

2. Approved the allotment of 1,16,500 equity shares to the employees of the Company, who has exercised the conversion option on the stock options vested on them from Bal Pharma Limited – Employee Stock Option Plan-2014.

The meeting commenced at 4.15 P.M and concluded at 5.30 P.M on 09.09.2024.

Please take this intimation on record.

For Bal Pharma Limited


Shailesh Siroya

Authorised Signatory



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. :080-41570811 / 13 / 19 Fax : 41570820